{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:51:49Z","timestamp":1778122309193,"version":"3.51.4"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":396,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.ctarc.2025.100875","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T07:35:22Z","timestamp":1738395322000},"page":"100875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7322-7092","authenticated-orcid":false,"given":"Oliver","family":"Illini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Sophie","family":"Lang-St\u00f6berl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Fabikan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Weinlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arschang","family":"Valipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian J.","family":"Hochmair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.ctarc.2025.100875_bib0001","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.3390\/cancers14174155","article-title":"HER2 in non-small cell lung cancer: a review of emerging therapies","volume":"14","author":"Uy","year":"2022","journal-title":"Cancers"},{"issue":"7008","key":"10.1016\/j.ctarc.2025.100875_bib0002","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/431525b","article-title":"Intragenic ERBB2 kinase mutations in tumours","volume":"431","author":"Stephens","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2025.100875_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107385","article-title":"Management of HER2 alterations in non-small cell lung cancer \u2013 the past, present, and future","volume":"186","author":"N\u00fctzinger","year":"2023","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2025.100875_bib0004","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.cllc.2022.10.008","article-title":"A phase I, open-label, dose confirmation, escalation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations","volume":"24","author":"Heymach","year":"2023","journal-title":"Clin. Lung Cancer"},{"issue":"16 supplement","key":"10.1016\/j.ctarc.2025.100875_bib0005","article-title":"Phase Ia\/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data","volume":"42","author":"Heymach","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2025.100875_bib0006","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1200\/JCO.2023.41.16_suppl.8545","article-title":"Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced\/metastatic solid tumors with HER2 aberrations: updated data","volume":"41","author":"Heymach","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2025.100875_bib0007","doi-asserted-by":"crossref","first-page":"TPS8654","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8654","volume":"42","author":"Johnson","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100875_bib0008","unstructured":"FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. 2024."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100875_bib0009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2 -mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100875_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100875_bib0011","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100875_bib0012","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2025.100875_bib0013","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2023.41.16_suppl.3501","article-title":"Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing\/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study","volume":"41","author":"Raghav","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T12:36:28Z","timestamp":1739018188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225000139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":13,"alternative-id":["S2468294225000139"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100875","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100875"}}